BMC Gastroenterology (Mar 2023)
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
- Sae Yumita,
- Sadahisa Ogasawara,
- Miyuki Nakagawa,
- Susumu Maruta,
- Tomomi Okubo,
- Norio Itokawa,
- Yotaro Iino,
- Masamichi Obu,
- Yuki Haga,
- Atsuyoshi Seki,
- Tadayoshi Kogure,
- Takamasa Ishino,
- Keita Ogawa,
- Kisako Fujiwara,
- Terunao Iwanaga,
- Naoto Fujita,
- Takafumi Sakuma,
- Ryuta Kojima,
- Hiroaki Kanzaki,
- Keisuke Koroki,
- Masanori Inoue,
- Kazufumi Kobayashi,
- Soichiro Kiyono,
- Masato Nakamura,
- Naoya Kanogawa,
- Tomoko Saito,
- Takayuki Kondo,
- Ryo Nakagawa,
- Shingo Nakamoto,
- Ryosuke Muroyama,
- Tetsuhiro Chiba,
- Ei Itobayashi,
- Masanori Atsukawa,
- Yoshihiro Koma,
- Ryosaku Azemoto,
- Kenji Ito,
- Hideaki Mizumoto,
- Jun Kato,
- Naoya Kato
Affiliations
- Sae Yumita
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Sadahisa Ogasawara
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Miyuki Nakagawa
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Susumu Maruta
- Department of Gastroenterology, Asahi General Hospital
- Tomomi Okubo
- Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital
- Norio Itokawa
- Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital
- Yotaro Iino
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Masamichi Obu
- Department of Gastroenterology, Kimitsu Chuo Hospital
- Yuki Haga
- Department of Gastroenterology, National Hospital Organization Chiba Medical Center
- Atsuyoshi Seki
- Department of Gastroenterology, Funabashi Municipal Medical Center
- Tadayoshi Kogure
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Takamasa Ishino
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Keita Ogawa
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Kisako Fujiwara
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Terunao Iwanaga
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Naoto Fujita
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Takafumi Sakuma
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Ryuta Kojima
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Hiroaki Kanzaki
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Keisuke Koroki
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Masanori Inoue
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Kazufumi Kobayashi
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Soichiro Kiyono
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Masato Nakamura
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Naoya Kanogawa
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Tomoko Saito
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Takayuki Kondo
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Ryo Nakagawa
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Shingo Nakamoto
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Ryosuke Muroyama
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Tetsuhiro Chiba
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Ei Itobayashi
- Department of Gastroenterology, Asahi General Hospital
- Masanori Atsukawa
- Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital
- Yoshihiro Koma
- Department of Gastroenterology, Kimitsu Chuo Hospital
- Ryosaku Azemoto
- Department of Gastroenterology, Kimitsu Chuo Hospital
- Kenji Ito
- Department of Gastroenterology, National Hospital Organization Chiba Medical Center
- Hideaki Mizumoto
- Department of Gastroenterology, Funabashi Municipal Medical Center
- Jun Kato
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- Naoya Kato
- Department of Gastroenterology, Graduate School of Medicine, Chiba University
- DOI
- https://doi.org/10.1186/s12876-023-02731-5
- Journal volume & issue
-
Vol. 23,
no. 1
pp. 1 – 11
Abstract
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to clarify the reality of HPD in patients with advanced hepatocellular carcinoma (HCC) who were treated with atezolizumab plus bevacizumab (Atez/Bev) using tumor dynamics. Methods Medical records of consecutive patients with advanced HCC who were treated with Atez/Bev were retrospectively reviewed. HPD was defined as a more than two- or fourfold increase in tumor growth rate (TGR) or tumor growth kinetics rate (TGKR) before and after treatment. Overall survival (OS) and baseline characteristics with or without HPD were analyzed. Results A total of 85 patients were included in the analysis. When HPD was defined as a twofold of TGR or TGKR, 8 patients (8/85, 9.4%) had HPD and 11 had PD without HPD. A total of 5 patients (5/85, 5.9%) were diagnosed with HPD and 14 with PD without HPD when HPD was defined as a fourfold of TGR or TGKR. No significant difference was observed in the baseline characteristics between HPD and non-HPD. Conclusion The prevalence of HPD in patients with advanced HCC treated with Atez/Bev was lower than those treated with nivolumab monotherapy. The HPD mechanism in ICI combined with antibodies targeting vascular endothelial growth factor (VEGF) remains to be elucidated.
Keywords
